Caplin Steriles gets US FDA approval for generic blood pressure drug
The company has so far developed and filed 13 ANDAs on its own and with partners, and received six approvals03-12-2019
03-12-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate03-12-2019
Caplin Point Laboratories Ltd - 524742 - DISCLOSURE OF RELATED PARTY TRANSACTIONS
DISCLOSURE OF RELATED PARTY TRANSACTIONS29-11-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - Notice Of Postal Ballot
Notice of Postal Ballot21-11-2019
Caplin Point Laboratories Ltd - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share certificate06-11-2019
Caplin Point Laboratories Ltd - 524742 - Re-Appointment Of Independent Director
Re-appointment of Independent Director30-10-2019
CAPLIN POINT LABORATORIES LTD. - 524742 - Un-Audited Financial Results For The Quarter/Half Year Ended September 30,2019
Un-audited Financial Results for the quarter/half year ended September 30,201930-10-2019
Caplin Point Laboratories Ltd - 524742 - EARNINGS CONFERENCE CALL ON OCTOBER 30, 2019
EARNINGS CONFERENCE CALL ON OCTOBER 30, 201925-10-2019
Caplin Point Laboratories Ltd - 524742 - Board Meeting Intimation for Considering The Un-Audited Financial Results For The Quarter/Half Year Ended September 30,2019.
CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2019 ,inter alia, to consider and approve the Un-audited Financial Results for the quarter/half year ended September 30, 201921-10-2019